What is doxorubicin liposomal?
Doxorubicin liposomal is a cancer (antineoplastic) medication. Doxorubicin liposomal interferes with the growth of cancer cells and slows their growth and spread in the body.
Doxorubicin liposomal is used to treat metastatic ovarian cancer and AIDS-related Kaposi's sarcoma.
Doxorubicin liposomal may also be used for purposes other than those listed in this medication guide.
What is the most important information I should know about doxorubicin liposomal?
Doxorubicin liposomal should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.
Serious side effects have been reported with the use of doxorubicin liposomal including: allergic reactions (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives); severe heart damage with prolonged use; decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; fever or chills; or signs of infection); severe nausea, vomiting, diarrhea, and loss of appetite; and others. Talk to your doctor about the possible side effects from treatment with doxorubicin liposomal.
Who should not use doxorubicin liposomal?
Do not use doxorubicin liposomal without first talking to your doctor if you have
poor bone marrow function;
received radiation therapy that encompassed the heart; or
previously received treatment with doxorubicin (Adriamycin, Rubex), doxorubicin liposomal (Doxil), daunorubicin (Cerubidine), daunorubicin liposomal (Daunoxome), idarubicin (Idamycin), or mitoxantrone (Novantrone).
The use of doxorubicin liposomal may be dangerous if you have any of the conditions listed above.
Doxorubicin liposomal is in the FDA pregnancy category D. This means that doxorubicin liposomal is known to be harmful to an unborn baby. Do not use doxorubicin liposomal without first talking to your doctor if you are pregnant. Discuss with your doctor the appropriate use of birth control during, and for several months following, treatment with doxorubicin liposomal if necessary.
Because of the potential for serious side effects in a nursing infant, breast-feeding should be avoided during treatment with doxorubicin liposomal.